pH-dependent uptake of Irinotecan and its active metabolite, SN-38, by intestinal cells

International Journal of Cancer

Volumn 83, Issue 4, 1999, Pages 491-496

  Kobayashi, Kunihiko ^a,b   Bouscarel, Bernard ^a,c,e   Matsuzaki, Yasushi ^d   Ceryak, Susan ^a   Kudoh, Shoji ^b   Fromm, Hans ^a  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

^b NIPPON MEDICAL SCHOOL   (Japan)

^c GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^d UNIVERSITY OF TSUKUBA   (Japan)

^e GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; IRINOTECAN;

ALKALINIZATION; ANIMAL CELL; ARTICLE; CANCER; CANCER CHEMOTHERAPY; CYTOTOXICITY; DRUG UPTAKE; ENTEROHEPATIC CIRCULATION; INTESTINE ABSORPTION; NONHUMAN; PH MEASUREMENT; PRIORITY JOURNAL; SYRIAN HAMSTER;

2,4-DINITROPHENOL; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOLOGICAL TRANSPORT, ACTIVE; CAMPTOTHECIN; CRICETINAE; DNA TOPOISOMERASES, TYPE I; DOSE-RESPONSE RELATIONSHIP, DRUG; HT29 CELLS; HUMANS; HYDROGEN-ION CONCENTRATION; INTESTINAL MUCOSA; ISOMERISM; MESOCRICETUS; TIME FACTORS;

EID: 0032833129     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19991112)83:4<491::AID-IJC10>3.0.CO;2-M     Document Type: Article

References (25)

1. AKIMOTO, K., KAWAI, A. and OHYA, K., Kinetic studies of the hydrolysis and lactonization of camptothecin and its derivatives, CPT-11 and SN-38, in aqueous solution. Chem. Pharm. Bull, 42, 2135-2138 (1994).
2. ARAKI, E., ISHIKAWA, M., IIGO, M., KOIDE, T., ITABASHI, M. and HOSHI, A., Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. Jpn. J. Cancer Res., 84, 697-702 (1993).
3. ATSUMI, R., OKAZAKI, O. and HAKUSUI, H., Pharmacokinetics of SN-38 [(+)-(4S)-4,11-Diethyl-4,9-dihydroxy-1H-pyrano [3′,4′:6,7]-indolizino [1,2-b]quinoline-3,14(4H,12H)-dione], a metabolite of irinotecan, after a single intravenous dosing of 14C-SN-38 to rats. Biol Pharm. Bull., 18, 1114-1119 (1995).
4. ATSUMI, R., SUZUKI, W. and HAKUSUI, H., Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion. Xenobiotica, 21, 1159-1169 (1991).
5. BLEIBERG, H. and CVITKOVIC, E., Characterisation and clinical management of CPT-11 (irinotecan)-induced adverse events: the European perspective. Europ. J. Cancer, 32A. Suppl. 3, S18-23 (1996).
6. BUGAUT, M., Occurrence, absorption and metabolism of short chain fatty acids in the digestive tract of mammals. Comp. Biochem. Physiol, 86B, 439-472 (1987).
7. BURKE, T.G. and MI, Z., The structural basis of camptothecin interactions with human serum albumin: impact on drug stability. J. med. Chem., 37, 40-46 (1994).
8. CHARMAN, W.N., PORTER, C.J., MITHANI, S. and DRESSMAN, J.B., Physiochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. J. pharm. Sci., 86, 269-282 (1997).
9. CHU, X.Y., KATO, Y., NIINUMA, K., SUDO, K., HAKUSUI, H. and SUGIYAMA, Y., Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats. J. Pharmacol. exp. Ther., 281, 304-314 (1997a).
10. CHU, X.Y., KATO, Y. and SUGIYAMA, Y, Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats. Cancer Res., 57, 1934-1938 (1997b).
11. CUNNINGHAM, D., PYRHÖNEN, S., JAMES, R.D., PUNT, C.J.A., HICKISH, T.S., HEIKKILA, R., JOHANNESES, T, STARKHAMMAR, H., TOPHAM, C.A., ONG, E., HERAIT, P. and JACQUES, C., A phase III multicenter randomized study of CPT-11 versus supportive care alone in patients with 5-FU-resistant metastatic colorectal cancer. Proc. Amer. Soc. clin. Oncol, 17, 1a (1998).
12. FASSBERG, J. and STELLA, V.J., A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J. pharm. Sci., 81, 676-684 (1992).
13. FUKUOKA, M., NIITANI, H., SUZUKI, A., MOTOMIYA, M., HASEGAWA, K., NISHIWAKI, Y, KURIYAMA, T., ARIYOSHI, Y, NEGORO, S., MATSUDA, N., NAKAJIMA, S. and TAGUCHI, T, for the CPT-11 Lung Cancer Study Group, A phase II study of CPT-I1, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J. clin. Oncol, 10, 16-20 (1992).
14. GORE, J. and HOINARD, C., Linoleic acid transport in hamster intestinal cells is carrier-mediated. J. Nutr., 123, 66-73 (1993).
15. HAAZ, M.C., RIVORY, L.P., RISHE, C. and ROBERT, J., Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A (CYP3A) and drug interactions. Proc. Amer. Assoc. Cancer Res., 38, 17 (1997) (Abstr.).
16. IKUNO, N., SODA, H., WATANABE, M. and OKA, M., Irinotecan (CPT-11) and characteristic mucosal change in the mouse ileum and cecum. J. nat. Cancer Inst., 87, 1876-1883 (1995).
17. KAWATO, Y., AONUMA, M., HIROTA, Y., KUGA, H. and SATO, K., Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res., 51, 4187-4191 (1991).
18. KOBAYASHI, K., BOUSCAREL, B., MATSUZAKI, Y., CERYAK, S. and FROMM, H., Uptake mechanism of irinotecan (CPT-11) and its metabolite (SN-38) by hamster intestinal cells. Gastroenterology, 114(4), A626 (1998a).
19. KOBAYASHI, K., SHINBARA, A., KAMIMURA, M., TAKEDA, Y., KUDO, K., KABE, J., HIBINO, S., HINO, M., SHIBUYA, M. and KUDOH, S., Irinotecan (CPT-11) in combination with weekly administration of cisplatin (CDDP) for non-small-cell lung cancer. Cancer Chemother. Pharmacol, 42, 53-58 (1998b).
20. LOKIEC, F., CANAL, P., GAY, C., CHATELUT, E., ARMAND, J.P., ROCHE, H., BUGAT, R., GONCALVES, E. and MATHIEU-BOUÉ, A., Pharmacokinetics of irinotecan and its metabolites in human blood, bile, and urine. Cancer Chemother. Pharmacol, 36, 79-82 (1995).
21. McCLOUD, E., MATHIS, R.K., GRANT, K.E. and SAID, H.M., Intestinal uptake of uridine in suckling rats: mechanism and ontogeny. Proc. Soc. exp. Biol. Med., 206, 425-430 (1994).
22. MOSMANN, T., Rapid colorimetiric assay for cellular growth and survival: application to proliferation and cytotoxicity assay. J. immunol. Methods, 65, 55-63 (1983).
23. RIVORY, L.P., BOWLES, M.R., ROBERT, J. and POND, S.M., Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase. Biochem. Pharmacol., 52, 1103-1111 (1996a).
24. RIVORY, L.P., RIOU, J.F., HAAZ, M.C., SABLE, S., VUIHORGNE, M., COMERSON, A., POND, S.M. and ROBERT, J., Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients. Cancer Res., 56, 3689-3694 (1996b).
25. TAKATSUNA. K., HAGIWARA, T., HIROHASHI, M., KATO, M., NOMURA, M., NAGAI, E., YOKOI, T. and KAMATAKI, T, Involvement of beta-glucuronidase in intestinal microflora in the intestinal toxicity of the antitumor camptothecin derivative irinotecan hydrochloride. Cancer Res., 56, 3752-3757 (1996).